Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by spammeon Jul 15, 2011 4:46pm

233 Views

Post# 18837279

RE: RE:Shrinkage in Shares - The $1500 POG Wall

My question is, how do you explain the price spread/variance between the two listings (TSX & AMEX)?
Stanley, It is call exchange rates $1.89 *.96=$1.8144 and a little bit of liquidity. You see conspiracy around the corner every time your stock is not behaving the way you want. Give it a rest.

Bullboard Posts

Canadian artificial intelligence ETFs